NAMUR, Belgium, Feb. 9,
2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX)
today announced that it will present at Source Capital
Group's 2nd Annual Disruptive Growth & Healthcare
Conference being held on February 15-16,
2017 in New York, NY.
Scott Powell, Executive Vice
President of Volition, will provide an update on Volition's
business, clinical, regulatory and operational milestones, as well
as the Company's recently announced product launch of its
Nu.QTM Colorectal Cancer Screening Triage Test.
Event:
|
Source Capital
Group's 2nd Annual Disruptive Growth & Healthcare
Conference
|
Date:
|
Wednesday, February
15, 2017
|
Time:
|
9:00 a.m. Eastern
Time
|
Location:
|
Convene, New York,
NY
|
Persons attending the conference who would like to schedule a
1-on-1 meeting with Volition management during the conference may
do so by contacting Tirth Patel of
Edison Advisors at tpatel@edisongroup.com or Scott Powell, Executive Vice President of
Volition, at S.Powell@volitionrx.com.
Check out the NEW Corporate Video and Website at
www.volitionrx.com
About Volition
Volition is a life sciences company focused on developing
diagnostic tests for cancer. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid --
an indication that disease is present.
Volition's goal is to make the tests as easy and simple to use,
for both patients and doctors, as existing diabetic and cholesterol
blood tests. Volition's research and development activities are
currently centered in Belgium as
the company focuses on bringing its diagnostic products to market
first in Europe, then in the U.S.
and ultimately, worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Sarah Roberts,
Vane Percy & Roberts
sarah@vanepercy.com
+44 (0)1737 821
890
|
|
Nucleosomics®, NuQ®, Nu.QTM and
HyperGenomics® and their respective logos are trademarks
and/or service marks of VolitionRx Limited and its subsidiaries.
All other trademarks, service marks and trade names referred to in
this press release are the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-source-capital-groups-2nd-annual-disruptive-growth--healthcare-conference-on-february-15-2017-300404879.html
SOURCE VolitionRx Ltd